Clinical trials: Immunization Programs
- Condition Immunization Programs
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Bordetella Pertussis, Whooping Cough
Pertussis Immunization Programs in Low Income Countries
Due to waning of infectious as well as vaccine immunity and lack of vaccination boosters, a large number of adolescents and adults are no longer immunized against Bordetella pertussis, the agent of whooping cough and consequently…
- Trial name
- PERILIC (NCT02983487)
- Testing
- Nasopharyngeal sampling, Blood Sampling
- Where
- 3 sites in Cambodia, Madagascar and 1 more
- Volunteers
- 3,587 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Bordetella Pertussis, Whooping Cough
Pertussis Immunization Programs in Low Income Countries - Ivory Coast
Due to waning of infectious as well as vaccine immunity and lack of vaccination boosters, a large number of adolescents and adults are no longer immunized against Bordetella pertussis, the agent of whooping cough and consequently…
- Trial name
- PERILIC-IC (NCT03388034)
- Testing
- Nasopharyngeal sampling, Blood Sampling
- Where
- 5 sites in Côte d’Ivoire
- Volunteers
- 789 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Hepatitis B
Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule
Hepatitis B virus (HBV) infection is an important global health problem, and the WHO adopted a strategy to eliminate HBV infection as a public health threat by the year 2030.
- Trial name
- NEOVAC2BK (NCT04029454)
- Testing
- birth dose vaccination against hepatitis B strategy
- Where
- 2 sites in Burkina Faso
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Malaria, Malaria Vaccines
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
GSK Biologicals in partnership with the Malaria Vaccine Initiative at PATH is developing a candidate malaria vaccine GSK 257049 for the routine immunization of infants and children living in malaria endemic areas.
- Trial name
- NCT00289185
- Testing
- RTS,S/AS02D, Engerix-B®, TETRActHib™
- Where
- Tanzania
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus (RSV)
Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
This was a non-interventional, prospective, multi-center study with no control group designed to assess the effectiveness of palivizumab in a population of infants at high-risk of serious Respiratory Syncytial Virus (RSV) illness…
- Trial name
- SUNRISE (NCT02282982)
- Volunteers
- 359 people
- Sponsor
- AbbVie
Malaria
Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen
This study is being done to assess the possibility of the potential integration of malaria vaccine into the EPI regimen. It will evaluate whether the malaria vaccine is safe and immunogenic in infants aged 6 to 10 weeks at first…
- Trial name
- NCT00436007
- Testing
- GSK 257049, Tritanrix™ HepB/Hib, Rouvax™
- Where
- 3 sites in Gabon, Ghana and 1 more
- Volunteers
- 511 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program
To measure the effectiveness of influenza vaccination in school children by comparing, between target(i.e., children are offered FluMist) and control (i.e., children are not offered FluMist) school families.
- Trial name
- NCT00192218
- Testing
- FluMist
- Where
- 2 sites in United States
- Volunteers
- 3,022 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Pneumococcal Infections
Study Evaluating Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Prevnar®
Primary Objective: To evaluate the impact of PCV7 vaccination on NP carriage rate of vaccine serotypes and serotype distribution Secondary Objective: To evaluate the impact of PCV7 vaccination on NP carriage of antibiotic…
- Trial name
- NCT00488371
- Testing
- Pneumococcal Conjugated Vaccine (Prevnar®)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer